Variable name;level;Overall;Yes;No;p;test
;n;262;175;87;;
Age;[0 -30);63;45 (71.4);18 (28.6);0.401;
;[30 -35);119;82 (68.9);37 (31.1);;
;[35 -40);76;45 (59.2);31 (40.8);;
;40+;4;3 (75);1 (25);;
Number of children;0;177;119 (67.2);58 (32.8);0.856;
;1;53;36 (67.9);17 (32.1);;
;More than 1;32;20 (62.5);12 (37.5);;
BMI;<18.5;16;4 (25);12 (75);0.003;
;25-29.9;46;34 (73.9);12 (26.1);;
;>=30;12;9 (75);3 (25);;
;18.5-24.9;181;123 (68);58 (32);;
Treatment center;Curie Paris;168;114 (67.9);54 (32.1);0.725;
;Curie St Cloud;94;61 (64.9);33 (35.1);;
Hereditary predisposition;No;159;109 (68.6);50 (31.4);0.601;
;Yes;46;29 (63);17 (37);;
Inflammatory BC;No;260;173 (66.5);87 (33.5);0.805;
;Yes;2;2 (100);0 (0);;
Clinical Tumor size (mm);;32.0 (20.2);36.8 (21.1);22.2 (13.8);<0.001;
Clinical N stage (TNM);N0;165;100 (60.6);65 (39.4);0.006;
;N1;96;75 (78.1);21 (21.9);;
SBR grade;Grade I;11;8 (72.7);3 (27.3);0.891;
;Grade II;96;63 (65.6);33 (34.4);;
;Grade III;154;103 (66.9);51 (33.1);;
Histological type;Lobular;6;3 (50);3 (50);0.060;
;NST;249;170 (68.3);79 (31.7);;
;Others;7;2 (28.6);5 (71.4);;
Neoajuvant chemotherapy;No;118;41 (34.7);77 (65.3);<0.001;
;Yes;144;134 (93.1);10 (6.9);;
Chemotherapy setting;Adjuvant;118;41 (34.7);77 (65.3);<0.001;
;NAC;144;134 (93.1);10 (6.9);;
Fertility preservation discussion;No;3;2 (66.7);1 (33.3);1.000;
;Yes;259;173 (66.8);86 (33.2);;
